PCRX Earnings

PCRX reported its earnings on 2026-02-26, showcasing a revenue of against an estimate of 196.99M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.9 by 0%. The stock experienced a -3.01% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following PCRX's earnings announcement on 2026-02-26, the stock price moved by -3.01% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, PCRX's stock price tends to shift by an average of 2.38% in the 10 days leading up to earnings and -2.15% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate PCRX's annual revenue to reach 186.87M, while the EPS is projected at 0.76. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PCRX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PCRX's stock price typically moves by 2.38% in the 10 days before its earnings and -2.15% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.76 and revenue of 186.87M.

The earnings call shows strong financial performance with revenue and margin improvements, alongside optimistic future guidance. Key growth drivers include EXPAREL's market expansion and improved reimbursement. The Q&A reveals management's confidence in growth strategies, despite some vague responses. The stock buyback plan and raised guidance further enhance positive sentiment. Overall, these factors suggest a positive stock price movement, although the lack of specific market cap information limits the prediction's precision.